TH137791A - Connected cyclopentane carboxylic acid derivative, replaced by amino acid. And the use of such substances as pharmaceutical substances - Google Patents
Connected cyclopentane carboxylic acid derivative, replaced by amino acid. And the use of such substances as pharmaceutical substancesInfo
- Publication number
- TH137791A TH137791A TH901001956A TH0901001956A TH137791A TH 137791 A TH137791 A TH 137791A TH 901001956 A TH901001956 A TH 901001956A TH 0901001956 A TH0901001956 A TH 0901001956A TH 137791 A TH137791 A TH 137791A
- Authority
- TH
- Thailand
- Prior art keywords
- substances
- formula
- relates
- receptor
- pharmaceutical
- Prior art date
Links
- 239000000126 substance Substances 0.000 title claims abstract 7
- 150000001413 amino acids Chemical class 0.000 title 1
- JBDSSBMEKXHSJF-UHFFFAOYSA-N cyclopentanecarboxylic acid Chemical class OC(=O)C1CCCC1 JBDSSBMEKXHSJF-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 6
- 102000004137 Lysophosphatidic Acid Receptors Human genes 0.000 claims abstract 5
- 108090000642 Lysophosphatidic Acid Receptors Proteins 0.000 claims abstract 5
- WRGQSWVCFNIUNZ-GDCKJWNLSA-N 1-oleoyl-sn-glycerol 3-phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP(O)(O)=O WRGQSWVCFNIUNZ-GDCKJWNLSA-N 0.000 claims abstract 4
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims abstract 4
- 201000010099 disease Diseases 0.000 claims abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 4
- 206010019280 Heart failures Diseases 0.000 claims abstract 2
- 210000001367 artery Anatomy 0.000 claims abstract 2
- 210000004204 blood vessel Anatomy 0.000 claims abstract 2
- 230000003511 endothelial effect Effects 0.000 claims abstract 2
- 239000003112 inhibitor Substances 0.000 claims abstract 2
- 208000028867 ischemia Diseases 0.000 claims abstract 2
- 208000010125 myocardial infarction Diseases 0.000 claims abstract 2
- 102000005962 receptors Human genes 0.000 claims abstract 2
- 108020003175 receptors Proteins 0.000 claims abstract 2
- 101000966782 Homo sapiens Lysophosphatidic acid receptor 1 Proteins 0.000 claims 1
- 102100040607 Lysophosphatidic acid receptor 1 Human genes 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 239000013543 active substance Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Abstract
DC60(22/07/52) การประดิษฐ์นี้เกี่ยวข้องกับสารประกอบตามสูตรI (สูตรเคมี)I โดยที่A,Y,Z,R3ถึงR6,R20,ถึงR22และR50มีความหมายดังระบุในข้อถือสิทธิซึ่งเป็นสารออกฤทธิ์ ที่มีค่าทางเภสัชกรรมกล่าวโดยเจาะจงสารประกอบดังกล่าวเป็นสารยับยั้งเอนโดทีเลียล ดิฟเฟอเรนชิเอชันจีนรีเซปเตอร์2(Edg2,EDG2)ซึ่งถูกแอคติเวตโดยกรดไลโซฟอสฟาทิดิก(LPA) และยังถูกเรียกว่าLPA1รีเซปเตอร์ด้วยและมีประโยชน์สำหรับการรักษาโรคอย่างเช่นโรคท่อเลือด แดงและเลือดแดงแข็ง,กล้ามเนื้อหัวใจตายเหตุขาดเลือดและหัวใจล้มเหลวเป็นต้นนอกจากนี้ การประดิษฐ์นี้ยังเกี่ยวข้องกับกระบวนการในการเตรียมสารประกอบตามสูตรI,การใช้สารดังกล่าว และองค์ประกอบทางเภสัชกรรมที่ประกอบรวมด้วยสารดังกล่าว DC60(22/07/09) This invention relates to a compound according to formula I (chemical formula)I, where A,Y,Z,R3 to R6,R20,to R22 and R50 have the meanings as specified in the claim, which is Active substance Of particular pharmaceutical value, such compounds are said to be endothelial inhibitors. Differential Chinese receptor 2 (Edg2, EDG2) is activated by lysophosphatidic acid (LPA) and is also called LPA1 receptor. And is useful for treating diseases such as blood vessel disease. Arterial and hardened arteries, myocardial infarction due to ischemia and heart failure, etc. In addition, The invention also relates to the process of preparing a compound according to Formula I, the use of which is and pharmaceutical compositions comprising such substances
Claims (1)
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TH137791B TH137791B (en) | 2014-10-03 |
| TH137791A true TH137791A (en) | 2014-11-03 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA32368B1 (en) | Carboxylic cyclopentane derivatives - intensive substituted acyl amino and used as drugs | |
| MX2012004739A (en) | Acylamino-substituted cyclic carboxylic acid derivatives and their use as pharmaceuticals. | |
| WO2008057802A3 (en) | Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same | |
| EA200870302A1 (en) | 1,3-DIOXANKARBONIC ACIDS | |
| WO2010093727A8 (en) | Quinazolinones as prolyl hydroxylase inhibitors | |
| EA201101672A1 (en) | SUBSTITUTED DERIVATIVES OF AMINOISAL ACID AS NEPRILISIN INHIBITORS | |
| EA201391786A1 (en) | HALOGEN-ALKYL-1,3-OXAZINS AS BACE1 AND / OR BACE2 INHIBITORS | |
| MA33745B1 (en) | Alternative pepperdines that increase the activity of p53 and the use of their compounds | |
| WO2008030412A3 (en) | Spiropiperidine beta-secretase inhibitors for the treatment of alzheimer's disease | |
| WO2011056985A3 (en) | Substituted heterocyclic compounds | |
| WO2013014204A3 (en) | 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals | |
| BR112012018253A2 (en) | OXYGEN-SUBSTITUTED 3-HETEROAROYLAMINO-PROPIONIC ACID DERIVATIVES AND THEIR USE AS DRUGS | |
| BR112014009910A2 (en) | 1- (5,6-Dichloro-1h-benzo [d] imidazol-2-yl) -1h-pyrazol-4-carboxylic acid meglumine salt formulations | |
| BR112014001587A2 (en) | substituted 3- (thiazol-4-carbonyl) - or 3- (thiazol-2-carbonyl) amino-propionic acid derivatives and their use as pharmaceuticals | |
| WO2011006935A3 (en) | Tetrazole derivatives | |
| EA201691962A1 (en) | AMIDOSED NITROGEN COMPOUNDS AS TNKS1 AND / OR TNKS2 INHIBITORS | |
| PT2523960E (en) | Heterocyclic carboxylic acid derivatives having a 2,5-substituted oxazolopyrimidine ring | |
| WO2011037833A3 (en) | Novel n-benzylamide substituted derivatives of 2-(acylamido)acetic acid and 2-(acylamido)propionic acids: potent neurological agents | |
| JP2012144532A5 (en) | ||
| TH137791A (en) | Connected cyclopentane carboxylic acid derivative, replaced by amino acid. And the use of such substances as pharmaceutical substances | |
| RU2011134414A (en) | FULVIC ACID COMBINATION FOR TREATMENT OF VARIOUS CONDITIONS AND DISEASES | |
| EA201400724A1 (en) | COMBINATION (3S, 3S ') 4,4'-DISULFANDIILBIS (3-AMINOBUTAN-1-SULPHEIC ACIDS) AND SECOND ANTIHYPERTENSIVE MEANS | |
| JP2017536355A5 (en) | ||
| MA34961B1 (en) | INHIBITORS OF CATHEPSIN C | |
| UY29550A1 (en) | DERIVATIVES OF (SULFAMOIL-ALQUIL) -AMIDE OF HETEROARIL-CARBOXYL ACID AS INHIBITORS OF THE XA FACTOR |